ARTICLE | Finance
Back in the game
Why Gimv came off the sidelines for Topas' series A
March 28, 2016 7:00 AM UTC
After spending the last few years exiting many of its biotech portfolio companies, Gimv is again putting capital to work in the space. The firm is picking up where it left off with a bet on an autoimmune play.
Last week, Gimv participated in a €14 million ($15.8 million) series A round for Topas Therapeutics GmbH, which spun out of Evotec AG (Xetra:EVT) to develop nanoparticle-based therapeutics that induce antigen-specific immune tolerance in the liver...